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1. Introduction
Sodium alendronate (hereinafter, AL-Na) is one of the most important drug substances of the
bisphosphonate class administered orally for the treatment of all types of osteoporosis.
Alendronate has a positive influence on all symptoms of osteoporosis by increasing bone
mineral density and pacient mobility, reducing the risk of osteoporotic fractures in all
vulnerabilities (vertebrae, hip, arm and femoral neck) and having an analgesic effect in bone
pain. The anti-resorptive mechanism of action of AL-Na is complex and involves effects at both
the molecular and the cellular level. Osteoclasts and their precursors are the target cells of AL-
Na and, by internalization, they absorb the AL-Na molecule from the surface of bone. At the
molecular level, AL-Na prevents the conversion of dimethyl-allyl pyrophosphate to geranyl -
geranyl - pyrophosphate. Besides the biochemical effects described above, AL-Na also
produces a number of effects at the cellular level, among which loss of brush border and
fractures in the osteoclast cytoskeleton. All these actions of AL-Na ultimately lead to an
increase in bone mineral density and to osteoclast-mediated inhibition of bone resorption. It
is important to note that the anti-resorptive effect of AL-Na occurs the day after the first dose,
the intensity of the therapeutical effect being directly dependent on the active substance dose
administered [1, 2]. The results of the Fosamax Fracture Intervention Trial Long-term Exten‐
sion (FLEX) showed that patients treated with AL-Na for 5 years presented an obvious increase
in bone mineral density in the femoral neck, as well as in the lumbar spine. The results of this
10-year study showed a 17.7% decrease in the risk of vertebral fracture compared with placebo
[3, 4]. Currently, AL-Na is used in daily (10 mg/tablet) or weekly (70 mg/tablet with or without
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2 800 I.U. of vitamin D3) conventional release tablets. Tablets with a higher concentration of
vitamin D3 (70 mg AL-Na/5600 IU cholecalciferol/tablet) have also been introduced in therapy
quite recently [5]. The exogenous intake of cholecalciferol contributes to the normalization of
calcium homeostasis in the body and to the optimization of the anti-resorptive effect caused
by AL-Na. Furthermore, it is known that a low level of vitamin D3 manifests in muscle
weakness which can cause accidents with high risk of fracture [6].Once-weekly administered
tablets (70 mg/tablet) have largely increased patient compliance with alendronate and led to
a reduction in the incidence of gastrointestinal side effects. Pharmacokinetic studies have
shown that oral doses of alendronate in the range 5-80 mg generate a bioavailability of 0.1-1%,
with a fraction of 50% of the amount deposited in the bone. In addition, it was shown that oral
administration of 10 mg alendronate daily and of 70 mg alendronate once-weekly generates
the same level of increase in bone mineral density: 5-6% in the vertebrae and 3-9% in the femoral
bone. Alendronate administered orally in the form of a solution (70 mg/vial) is intended for
patients with deficiencies in swallowing. The latest alendronate formulation approved by Food
and Drug Administration (FDA) and European Medicines Evaluation Agency (EMEA) is the
association of 70 mg alendronate with 2800 I.U. vitamin D in immediate release tablets [7, 8].
According to FDA guidelines, there is no deadline or optimal duration for the treatment with
AL-Na. The treatment with AL-Na is recommended for as long as necessary along with regular
reassessment of patients (at intervals of no longer than five years) in order to determine bone
mineral density and fracture risk [9].
However, low oral bioavailability (under 1%) is the most important disadvantage of AL-Na.
It is caused by several factors such as: low permeability due to its negatively charged molecules
(AL belongs to the 3rd class of biopharmaceutical classification system); short plasma half-time
(T½ = 0.5-2 h); its chelatation by Ca2+ ions resulting in non-absorbable complexes. Research in
bisphosphonates in general aims to increase the bioavailability of these substances, to decrease side
effects, to increase adherence to treatment especially for elderly patients. AL-Na has been in the
attention of drug researchers and literature has presented a large number of studies on this
topic. Investigations conducted in the formulation of alendronate sodium are directed to
conventional pharmaceutical forms (solutions, emulsions, gels) as well as to modified-release
forms (matrix tablets, microemulsions, micro– and nanoparticulate drug delivery systems)
administered on various routes (Table 1).
In this study we have investigated the possibility of improving the oral bioavailability of AL-
Na by including it in hydrophilic matrix tablets based on various sorts of Carbopol. The role
of chitosan (CHT) and trimethyl chitosan (TMC) as AL-Na absorption enhancers was also
researched.
Carbopol polymers form an important class of excipients used for the formulation and
preparation of sustained release hydrophilic matrix tablets. Carbopols were synthesized and
patented in 1957 [24]. Since then, a variety of therapeutic agents (such as the agents in the 3rd
group of the biopharmaceutical system of drug classification: atenolol, verapamil, theophyl‐
line, metoprolol, ranitidine, etc.) have been formulated and prepared in different Carbopol-
based formulations with controlled release [25-30].
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Administration route Pharmaceutical dosage form References
Oral route
Modified-release tablets:
1. HPMC-based matrix tablets with different degrees of viscosity;
2. Gastro-resistant tablets using various sorts of ethyl cellulose and acrylic
derivatives as coating agents(Aquacoat ECD, Eudragit L30, Eudragit
L-30-D55)
[10]
[11]
Effervescent tablets [12, 13]
Solutions [14]
H/L Microemulsions with Captex 200 ® and lecithin as emulsifier [15]
Microparticulate therapeutic systems based on Eudragit S100/HPMC PLGA [16-18]
Gingival-dental mucosa Carbopol-based gels [19]
Vaginal mucosa HPMC-based gels [20]
Nasal mucosa Microparticulate therapeutic systems based on HPMC as unique excipient orassociated with PVP [21]
Transcutaneous
Reservoir-type transdermal therapeutic systems based on acrylic polymers in
combination with various percutaneous absorption promoters: lauric
acid, oleic acid, linoleic acid, myristic acid
[22]
Gels prepared with different sorts of Duro-Tak® (acrylic acid
copolymers) using propylene glycol and fatty acids as absorption
promoters (lauric acid, oleic acid, linoleic acid and myristic) at various
concentrations
[23]
Table 1. Examples of studies focused on increasing AL-Na bioavailability
From the chemical point of view, Carbopols are crosslinked polymers of acrylic acid (Figure
1), insoluble in water, characterized by a high degree of hydration.
 
C C 
C 
H H 
H 
n HO O 
Figure 1. General chemical structure of Carbopol polymers
According to the literature, Carbopol polymers generally exhibit good compressibility
characteristics, and this achieves compression at low pressures; are compatible with other
matrix forming hydrophilic agents and many excipients; may help mask taste and have
bioadhesive properties [31].
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In the formulations studied, we used three Carbopol sorts with different crosslinking degrees:
Carbopol 971 C (C 971), Carbopol 71 C (C 71) and Carbopol 974 C (C 974). These polymers are
obtained by the crosslinking reaction of acrylic acid with allyl penta erythrol, followed by a
polymerization reaction in ethyl acetate and neutralization with aqueous potassium hydroxide
1-3%. Although C 971 and C 974 are obtained by a similar technological process, the difference
is that sort C 971 has a lower level of crosslinking agent compared to C 974. C 71 is the granular
form of C 971 recommended to be used in direct compression [32-34]. Unlike the hydrophilic
linear polymers soluble in polar solvents, whose absorption capacity is dependent on molec‐
ular weight, crosslinked Carbopol polymers are insoluble in water, since crosslinking degree
is the determinant parameter of he matrix absorption capacity [35-37].
2. Investigations on the influence of carbopol sort on the release of
alendronate sodium from modified release matrix tablets
Prior to this research, in our department of Pharmaceutical Technology we have also studied
the influence of the concentration of Carbopol on the hydration and erosion characteristics of
matrices in order to establish the optimal conditions for the development of these formulations
[38-40]. Based on these results, in the present study we introduced 15% hydrophilic matrix
forming polymer in the formulation. We used three sorts of Carbopol with different cross-
linking degrees as matrix generating polymers: C 71 to C 971, polymers with a low of cross‐
linking degree, and C 974, a Carbopol with a high crosslinking degree. The research conducted
has been focused on investigating the influence of the Carbopol sort on the release of alendr‐
onate from modified release matrix tablets.
2.1. Materials and methods
2.1.1. Materials
Alendronate sodium trihydrate (Apotex Pharmaceutics INC, USA), Carbopol 974 P NF, 971 P
NF, 71 G NF (Noveon Inc.), Ludipress LCE (BASF), Aerosil 200 (Degussa), Magnesium stearate
(Union Derlivan S.A. Spain).
2.1.2. Methods
2.1.2.1. Preparation of matrix tablets
Three formulations of alendronate sodium matrix tablets were prepared by the method of
direct compression in the Korsh EK0 tablet machine (punch diameter of 9 mm, 8 to 10 kN
compression force). As matrix forming polymer, formulations denoted F1, F2, F3 contain, as
follows: 15% C 71 in F1, 15% C 971 in F2, and a mixture of 15:2% C 971:C974 – 15:2% in F3
(Table 2).
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Ingredients (mg %) FormulationF1 F2 F3
C 71 15 – –
C 971 – 15 15
C 974 – – 2
AL-Na 13.05 13.05 13.05
Mg Stearate 0.5 0.5 0.8
Aerosil – 0.5 1.5
Ludipress LCE 71.45 70.95 67.65
Table 2. Formulations of matrix tablets with AL modified release based on Carbopol
2.1.2.2. “In vitro” dissolution investigations
“In vitro” dissolution tests were carried out on a SR 8 Plus Series (AB & L Jasco) device, under
the following experimental protocol: dissolution medium: pH 1.2 solution (0.1 N HCl) for the
first 2 hours (a medium simulating gastric fluids) and solution pH 6.8 (phosphate buffer
solution) for the next 10 hours (a medium simulating intestinal fluids); Apparatus 2 (paddle);
bath temperature: 37ºC±0.5 ºC; rotation speed: 50 rpm; sampling interval was set to every hour
during the 12 hours of the test (at every collection, 7 ml of sample were replaced with the same
volume of medium).
One sample from the aliquot was subjected to the derivation and dosage procedure described
in the USP monography for the HPLC analysis of sodium alendronate. The quantitative
determination equipment included the following modules: HPLC type HP 1090 series II
provided with a diode array detector, UV-VIS spectrophotometer Agilent technologies 8453
and Zorbax C18 column. The mobile phase was a mixture of methanol, acetonitrile and water
in the following proportions: 17.5:17.5:65. Mobile phase flow was set at 0.3 mL/min., the
injection volume was 20μL and the detection was performed at 266 nm [41]. All the experi‐
ments were performed in triplicate.
Quantitative data were presented as mean ± standard deviation and statistical analysis was
performed using a one-way analysis of variance (one-way ANOVA). A comparison between
two means was made using Tukey's test, with statistical significance set at p < 0.05.
2.1.2.3. The analysis of the difference factor (f1) and the similarity factor (f2)
The two factors assessing the AL release profile in the investigated formulations were
calculated according to the following equation:
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where: n = the number of sampling time points, Rt = released AL percentage of the reference
formula at time point t, Tt = released AL percentage of the test at time point t and log10x
represents the logarithm of x to the base 10 [42].
Difference factor f1 is a measure for quantifying the differentiation degree of the release profile
followed by a drug substance in the formulation. The value of this factor is in the interval 0 -
50. The analogy degree varies inversely with f1 value. Thus, a value closer to 0 indicates a high
similarity between two or more compared formulations. When the dissolution profile between
the tested and the reference formula is identical, f1 is 0 and increases with the dissimilarity
between the formulas analyzed. In general, the values of the f1 factor in the range 0-15
correspond to very small differences between the formulations tested, while values greater
than 15 indicate major differences in the release profiles of the drug substances in the compared
formulations.
Similarity factor f2 is a parameter commonly used to compare the dissolution profiles of the
solid oral pharmaceutical forms.
When two dissolution profiles of the drug substance are similar, f2 is in the range of 50-100 [43,
44]. According to the FDA guidelines in force, the values of the f2 similarity factor included
between 50 and 100 show a high degree of similarity (≥ 90%) between the release profiles of
the tested formulation against the reference formulation. Theoretically, values of the similarity
factor f2 smaller than 50 are accepted in the interpretation of the in vitro dissolution tests.
Mention should be made that these values show a similarity <90% between the formulas
analyzed.
Note that these two parameters are accepted and recommended by international quality
guidelines for the comparative evaluation of the release profile of two or more formulations
compared to a reference formulation, as can be seen in equations 1 and 2. While EMEA has
not issued any regulations on the determination and analysis of difference factor f1 and
similarity factor f2, FDA and USP regulate the applicability of these factors for the comparison
of the release profile of two or more pharmaceutical formulations by the following clarifica‐
tions: 1. release profiles between two or more formulas can be compared only when the
dissolution test includes a minimum of 12 sampling points; 2 the conditions of the in vitro
dissolution test should be identical for the reference formulation and for the tested formula‐
tions [45-47].
2.2. Results and discussions
Figure 2 presents the results obtained from the in vitro dissolution test for the studied formu‐
lations.
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Figure 2. In vitro dissolution profile for AL in hydrophilic matrix tablets based on Carbopol
We can see from the results obtained that the dissolution profile of alendronate sodium in
formulation F2 based on C 971 is superior to other formulations (99.7889% AL-Na released; t
= 12 hours). In theory this result was not foreseeable because C 71 and C 971, the polymers in
formulas F1 and F2, have the same degree of crosslinking, sort C71 actually having flow
properties optimized by the granular particle form.
The influence of the crosslinking degree of the polymer in the formulation was also highlighted
by the pH value of the dissolution medium. Thus, at acidic pH 1.2 simulating gastric fluids, C
71 and C 971, which are polymers with a low degree of crosslinking, showed a uniform
hydration resulting in a uniform release of alendronate sodium in the matrix gel layers.
C 974, a polymer with a high degree of crosslinking, optimizes the retardation effect at gastric
level through the closely crosslinked gel structure which acts as an element that reduces the
diffusion of the drug substance in the hydrated matrix layers during the first hours of the test
and accelerates this process after the total hydration of the matrix.
Finally, after performing the dissolution test within 12 hours, we found that the dissolution
profile of alendronate sodium is identical in F1, the formula based on C 71, and in F3, the
formula in which we associated C 974 as well (F1 = 85.1128% AL-Na released; F3 = 85.5984%
AL-Na released), specifying that sort C 974 generates a slow dissolution profile within the first
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two hours of the test, at pH 1.2 (F1 = 44.9356% Na released; F2 = 46.5233% AL-Na released, F3
= 28.0566% AL-Na released, t = 2 hours).
The different behavior as regards the dissolution profile of alendronate sodium in modified
release matrix tablets is also confirmed by the results obtained in the determination of f1, the
difference factor, and f2, the similarity factor (Table 3).
Reference formula (Rt) Test formula (Tt) f1 f2
F1 F2 25.149 37.041
F1 F3 12.608 50.940
F2 F3 26.9546 34.1921
Table 3. Values of f1 and f2 factors obtained in the comparative analysis F1-F3
In the comparative analysis of the three formulations studied, the difference factor f1 has values
> 0. The similarity factor f2, which is the most representative for the comparison of the disso‐
lution profile of solid dosage forms also has values that indicate a different dissolution profile
for the three formulations investigated (f2 <50), with the exception of the comparison F1,
reference, F3, test, when f2 = 50, 940. We estimate that this value is determined by the evolution
of the release pattern of AL-Na towards the end of the in vitro dissolution test, in 6.8 buffer
system because there were no significant differences between the two formulas during the first
two hours of the test, under conditions of simulated gastric fluid.
2.3. Conclusions
The results of the in vitro dissolution test reveal that every sort of Carbopol influences the
release profile of alendronate sodium in matrix tablets with modified release. The crosslinking
degree of Carbopol is the defining element of the release properties of hydrophilic matrix
tablets. Sorts C 71 and C 971, with a low degree of crosslinking, hydrate much better at pH 1.2,
a phenomenon which facilitates the dissolution of alendronate sodium, its diffusion through
the gel layers of the matrix, and therefore, the release of a greater amount of drug substance
compared to formula F3, in which we associated C 974, a high crosslinking polymer, which
causes a slowing of the hydration process. The influence of the crosslinking degree of Carbopol
also manifests at pH 6.8; F2, the formula based on C 971, generated a release profile of AL-Na
superior to formula F3, in which we associated C 974 and C 971, and to formula F1 based on
C 71, respectively.
The different dissolution profile of alendronate sodium in modified release matrix tablets
based on Carbopol is further confirmed by the values of the two control parameters f1 and f2.
The similarity factor f2 is set to 50.940, little over 50, the lower limit of the acceptance criteria,
when comparing F1 as reference formulation and F3 as test formulation, but this value is
determined by the percentage of sodium alendronate dissolved in the second half of the period
of the dissolution test, after t = 6 hours. In the first part of the test, especially in the first two
hours, at pH 1.2, the two formulations have very different dissolution profiles.
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3. Investigation of the influence of some absorption promoters on the
release of alendronate sodium in modified release matrix tablets
Chitosan is a natural polysaccharide produced by the partial deacetylation of chitin which
includes in its structure two copolymers: N-acetylglucosamine and glucosamine (Figure 3).
This biodegradable and biocompatible polymer was investigated in various pharmaceutical
formulations as absorption promoter, excipient for controlled release tablets or bio-mucoad‐
hesive preparations [48].
Chitosan is soluble in acidic media, pH < 6.5, when the amino groups in its structure are
protonated. At pH values > 7, the solubility of chitosan is lower, the occurrence of the transition
from the solution to the gel state, which gives chitosan unique properties as an absorption
promoter for the oral administration of hydrophilic macromolecular substances including
peptides and proteins [49-52]. Some quaternary chitosan derivatives, for example, trimethyl
chitosan (TMC), are soluble in a higher pH range (pH=1-9) in a concentration of up to 10% m/
m, which results in widening the scope and applicability in this field.
The main action mechanism of CHT and TMC as absorption promoters is to open the inter‐
cellular junctions at membrane level, as a result of the interaction between CHT or its positively
charged derivative and the negative charges of the sialic acid present in the intestinal mucosa.
The absorption of the drug substance is therefore facilitated by para- and transcellular
mechanisms [53-58].
In this study we aimed to analyze the influence of the two main absorption promoters, CHT
and TMC, on the release of alendronate sodium in modified release matrix tablets based on
Carbopols.
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Figure 3. Chitosan - chemical structure
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3.1. Materials and methods
3.1.1. Materials
Sodium alendronate trihydrate (Apotex Pharmaceutics INC, USA), Carbopol 974 P NF, 971 P NF,
71 G NF (Noveon Inc.), Ludipress LCE (BASF), Aerosil 200 (Degussa), Magnesium stearate (Union
Derlivan S.A. Spain), high molecular weight Chitosan (CHTh) (degree of deacetylation > 85%,
Aldrich), N - Trimethyl chitosan (G.L.S. Chemicals & Materials, India).
3.1.2. Methods
3.1.2.1. Preparation of matrix tablets
Nine alendronate sodium matrix tablets formulas were formulated and subjected to direct
compression in a tablet machine Korsh EK0 (punch diameter 9 mm, 8.10 kN compression
force). Table 4 presents the raw materials used in the preparation of studied formulations.
Ingredients (mg %)
Formulation
F1 F2 F3 F4 F5 F6 F7 F8 F9
C 71 15 – – 15 – – 15 – –
C 971 – 15 15 – 15 15 – 15 15
C 974 – – 2 – – 2 – – 2
CHT – – – 6 6 6 – – –
TMC – – – – – – 6 6 6
AL 13.05 13.05 13.05 13.05 13.05 13.05 13.05 13.05 13.05
Mg stearate 0.5 0.5 0.8 0.5 0.5 0.8 0.5 5 0.8
Aerosil – 0.5 1.5 – 0.5 1.5 – 5 1.5
Ludipress LCE 71.45 70.95 67.65 65.45 64.95 61.65 65.45 64.95 61.65
Table 4. Pharmaceutical formulations of modified release matrix tablets with AL-Na based on Carbopols, with
absorption promoters
3.1.2.2. “In vitro” dissolution studies
“In vitro” dissolution tests were carried out on a SR 8 Plus Series (AB & L Jasco) device, under
the following experimental protocol described in section I. The tests were carried out on a total
of six tablets and the results shown are the average of the six determinations.
The analysis of the difference factor f1and similarity factor f2 was performed according to the
equations described in Section I.
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3.2. Results and discussions
The results of the in vitro dissolution test shown in Figure 4 reveal that the AL-Na release profile
of the Carbopol-based matrix tablets is maintained even in the presence of CHT. It is worth
noting that the released AL-Na amount for formula F5 is approximately 5% lower than for
formula F2 without CHT. This result can be explained by the different behavior of CHT at the
two pH values.
Figure 4. In vitro AL dissolution profile in F1-F6 formulas
To reveal the influence of CHT on the alendronate sodium release profile in modified release
matrix tablets, we calculated the two control factors f1 and f2. The results obtained are presented
in Table 5 and show that the dissolution profile is different in formulations F4 and F5 compared
to formulas F1 and F2. The comparative analysis of formula F6 as test and formula F3 as
reference led to a similarity factor value f2 greater than 50 (f2 = 57.187), which means that CHT
does not alter the dissolution profile for this formulation. We assume that the mechanism by
which CHT influences AL-Na dissolution is based on the low solubility of CHT at pH 6.8. In
the case of F6, there is also the influence of C 974, which, as we noted in the previous section,
due to its high crosslinking degree, causes a slower hydration of the matrix. In this context we
argue that between CHT and C 974 there is a synergism of action on the release profile of
alendronate sodium in modified release matrix tablets.
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Reference formula (Rt) Test formula (Tt) f1 f2
F1 F4 28.991 31.947
F2 F5 12.422 46.748
F3 F6 10.799 57.187
Table 5. Values of f1 and f2 factors obtained in the comparative analysis F1-F3 versus F4-F6
The comparative results of TMC-containing formulations F7-F9 to formulations F1-F3 are
shown in Figure 5.
Figure 5. In vitro AL dissolution profile in F1-F3-F7-F9 formulas
From the analysis of the data obtained we find that all formulas in which we introduced TMC
provide an alendronate sodium release in percentages above 90% during the 12 hours of the
dissolution test. For this absorption promoter as well we assume that the influence on the
dissolution profile of AL-Na is based on the TMC optimal solubility in the two dissolution
media, a property which determined the proper hydration of the matrix tablet, thus facilitating
the diffusion and release of alendronate sodium in the matrix. Difference factor f1 and similarity
factor f2 have values that reveal for formulations F7-F9 a different release profile compared to
reference formulations F1-F3 (Table 6).
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Reference formula (Rt) Test formula (Tt) f1 f2
F1 F7 23.247 39.942
F2 F8 13.119 47.307
F3 F9 27.969 39.230
Table 6. Values of f1 and f2 factors obtained in the comparative analysis F1-F3 versus F7-F9
3.3. Conclusions
The comparative analysis of the results obtained from the in vitro dissolution test showed that
formulas containing absorption promoters have an alendronate sodium dissolution profile
that differs from the formulas of the modified release matrix tablets based on Carbopol without
absorption promoters, test formulas (F1-F3). This conclusion is confirmed by the values of the
two parameters assessing the dissolution profile: difference factor f1 and similarity factor f2.
The influence of absorption promoters on the AL-Na dissolution profile in the studied
modified release matrix tablets can be assigned to the different solubility of CHT and TMC in
the two dissolution media.
4. Assessment of the release kinetics of alendronate sodium in modified-
release matrix tablets
The analysis of the release kinetics of a drug substance from a dosage form is particularly
important in characterizing and defining the pharmacotechnical and biopharmaceutical
properties of that particular preparation. In the case of the modified release tablets based on
matrix forming hydrophilic polymers, in order to determine the mechanism by which the drug
is released and its evolution over time, the understanding of its kinetic release profile is a
prerequisite.
The objective of this study is to identify a representative pattern for each formulation studied;
taking into account the multiple formulation factors that may influence drug substance release
from the modified-release matrix tablet.
4.1. Materials and methods
4.1.1. Materials
Sodium alendronate trihydrate (Apotex Pharmaceutics INC, USA), Carbopol 974 P NF, 971 P NF,
71 G NF (Noveon Inc.), Ludipress LCE (BASF), Aerosil 200 (Degussa), Magnesium stearate (Union
Derlivan SA Spain), high molecular weight chitosan (CHTh) (degree of deacetylation > 85%,
Aldrich), N - Trimethyl chitosan (G.L.S. Chemicals & Materials, India).
Hydrophilic Matrix Tablets Based on Carbopol for Improving the Oral Bioavailability of Sodium Alendronate — …
http://dx.doi.org/10.5772/59510
143
4.1.2. Methods
4.1.2.1. Preparation of matrix tablets
Nine formulations of matrix tablets with alendronate sodium were prepared by the direct
compression method according to data presented in Table 4, section II.1.
4.1.2.2. “In vitro” dissolution studies
“In vitro” dissolution tests were carried out on a SR 8 Plus Series device, under the following
experimental protocol described in section I. The tests were carried out on a total of six tablets
and the results shown are the average of the six determinations.
4.1.2.3. Data fitting and kinetics of drug release
The kinetics of AL-Na release from the formulations studied was analyzed by fitting on five
mathematical models according to the following equations:
The equations corresponding to the models applied in the study are:
0The zero-order kinetics: tM K t= × (3)
The first-order kinet 100i ( )cs: 1 k ttM e- ×= × - (4)
0.5Higuchi release model: t HM K t= × (5)
The Korsmeyer-Peppas relea ( 0.45)semodel: nt pM K t n= × = (6)
The Hopfenberg release model 100 [1 (1: ) ] ( 2; 3)nt HFM K t n n= × - - × = = (7)
where:
Mt = the amount of the drug dissolved at time t;
K0 = zero order rate constant;
K = first order rate constant;
KH = Higuchi rate constant;
KP = Korsmeyer-Peppas rate constant;
KHF = Hopfenberg rate constant;
n = the release exponent which characterizes the mechanism of drug release;
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t = time
Data fitting was performed by linear and nonlinear regression, using Matlab 7.1 software.
The Akaike index (AIC) and the correlation coefficient R2 were the criteria for the selection of
the model which describes with the highest fidelity the release profile for each formulation
studied. The best model prediction requires that the value of R2 is as close as possible to 1, and
the Akaike index has the smallest values [59-61].
The two model prediction parameters were calculated according to the following equations:
ln( / ) 2AIC n SSR n p= × + × (8)
where:
n = number of data points;
SSR = sum of squared errors;
p = number of estimated parameters.
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where:
yi = data obtained experimentally;
y∧i = values approximated by the model;
y¯ = average of experimental values
4.2. Results and discussions
The results obtained from fitting data on the five experimental models are shown in Table 7
and Figures 6-11.
Analyzing these data we can see that the zero-order release kinetic model is not representative
for the formulations studied (Figure 6); this conclusion was predictable considering the data
in the literature according to which this model is representative for the description of the
release profile of drug substances in osmotic systems with a constant speed independent of
the concentration (62-65). Mention should be made that the inclusion in the formula of C 74, a
polymer with a high degree of crosslinking which causes a reduction in the rate of matrix
hydration in an acidic environment, has led to good values of parameter R2. However, the
values of the Akaike index are not representative as to validate the zero-order kinetic release
model for the formulations containing this polymer (Table 7).
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The fitting of data from the nine formulas analyzed on the Higuchi and Korsmeyer-Peppas
models confirms the release of alendronate sodium in Carbopol-based matrix tablets by a
process of diffusion. The values of the parameters of the equation corresponding to the Higuchi
model are representative enough to suggest that the release of the active substance in the
studied matrices occurs through a diffusion process based on Fick's law according to which
the release of the active substance is directly proportional to the square root of time. The
Korsmeyer-Peppas model, where n is equal to 0.5 defines the active substance release through
a phenomenon of Fickian diffusion from plane shapes. Fitting on this model is further
substantiated by the data obtained in previous studies in which we have investigated the
hydration behavior of matrix tablets, when we found an increase in direct proportion between
the diameter and the thickness of the matrix, leading to the preservation of the plane geometric
shape [39, 40].
Kinetic
model
Parameters
of model
Formulation
F1 F2 F3 F4 F5 F6 F7 F8 F9
Zero-order
K0 8.3238 10.2973 7.6325 7.9905 9.4400 7.8339 9.6863 8.8962 9.6104
R2 0.8401 0.9073 0.9511 0.8678 0.8990 0.9678 0.7391 0.8765 0.9036
AIC 73.12 72.36 59.09 70.98 70.50 50.12 82.49 73.56 72.38
First-order
K 0.1900 0.2500 0.1200 0.1700 0.2100 0.1500 0.2600 0.1800 0.2100
R2 0.9371 0.9758 0.9572 0.9138 0.9677 0.9460 0.9514 0.9308 0.9624
AIC 57.95 43.41 48.59 59.70 44.21 52.35 55.10 56.43 48.44
Higuchi
KH 24.7646 30.3197 22.2784 23.7095 27.7771 22.5600 29.1919 26.4044 28.3790
R2 0.9652 0.9885 0.9720 0.9646 0.9728 0.9391 0.9364 0.9763 0.9871
AIC 42.33 32.38 37.67 41.67 41.41 54.16 56.61 40.81 32.29
Korsmeyer-
Peppas
KP 27.4199 33.5240 24.6139 26.2487 30.7108 24.8812 32.3696 29.2325 31.3944
R2 0.9726 0.9862 0.9631 0.9697 0.9697 0.9214 0.9565 0.9814 0.9872
AIC 37.12 36.96 42.47 37.41 43.82 57.80 50.42 34.65 30.73
Hopfenberg
(n=2)
KHF 0.0548 0.0844 0.0495 0.0521 0.0679 0.0517 0.0686 0.0612 0.0703
R2 0.9160 0.9835 0.9631 0.9228 0.9575 0.9806 0.08664 0.9499 0.9771
AIC 65.57 47.84 50.97 64.66 54.60 41.43 73.27 65.06 58.29
Hopfenberg
(n=3)
KHF 0.0405 0.0706 0.0363 0.0383 0.0521 0.0382 0.0522 0.0461 0.0545
R2 0.9324 0.9732 0.9562 0.9290 0.9672 0.9794 0.9022 0.9578 0.9840
AIC 62.95 44.36 48.73 62.55 49.26 42.77 70.05 62.21 53.58
Table 7. Parameter values of the mathematical equations corresponding to the evaluation models of release kinetics
and their predictability indicators
Data fitting on the Hopfenberg model revealed the presence and involvement of the erosion
phenomenon in the process of release of alendronate sodium. The prediction parameter R2 has
acceptable values (> 0.90) for all formulations studied, but the Akaike index does not allow the
validation of this model, regardless of the value of n. According to data obtained from the
analysis of the hydration behavior of matrices, erosion increases after 7-8 hours after the
introduction of the matrix in the dissolution medium. Figures 10-11 show a good fitting of the
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model particularly for formulations based on C 971, C 971 associated with C 974, as well as in
similar formulas in which we introduced CHT and TMC after moment 6-7 of the study.
Therefore, we consider that the Akaike index values are determined by the nonlinearity of the
erosion process.
Figure 6. The fitting plot of the AL-Na dissolution profiles from formulations F1-F9 with the zero-order kinetics model
Figure 7. The fitting plot of the AL-Na dissolution profiles from formulations F1-F9 with the first-order kinetics model
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Figure 8. The fitting plot of the AL-Na dissolution profiles from formulations F1-F9 with the Higuchi model
Figure 9. The fitting plot of the AL-Na dissolution profiles from formulations F1-F9 with the Korsmeyer-Peppas model
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Figure 10. The fitting plot of the AL-Na dissolution profiles from formulations F1-F9 with the Hopfenberg (n=2) model
Figure 11. The fitting plot of the AL-Na dissolution profiles from formulations F1-F9 with the Hopfenberg model (n=3)
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4.3. Conclusions
The results obtained showed good data fitting on the Higuchi model for all formulations
studied, which leads to the conclusion that AL-Na release from hydrophilic matrix tablets
occurs through a diffusion process based on Fick's law. In addition, the results obtained when
fitting data on the Korsmeyer-Peppas mathematical model is an additional argument for
considering diffusion as the main mechanism of AL-Na release from flat modified-release
hydrophilic matrix tablets. The Hopfenberg model applied to modified-release matrix tablets
with a complex formulation based on combinations of matrix-forming polymers in order to
highlight the involvement of erosion in the process of active substance release generated a
good fitting of the data in the analysis of the correlation coefficient R2, but the Akaike index
has high values, which does not allow the validation of the model. Data analysis shows that
in the second half of the duration of the dissolution test, the data obtained experimentally
generate a better fitting for the Hopfenberg model both for n = 2 and for n = 3. In conclusion,
the data obtained from fitting on the Hopfenberg model confirms the involvement of erosion
as a mechanism of alendronate sodium release from modified-release hydrophilic matrix
tablets, but the predictive parameter values of the model do not allow the validation of this
model due to the nonlinearity of erosion.
In conclusion, Fickian diffusion is the main mechanism of alendronate sodium release from
modified-release hydrophilic matrix tablets and erosion is the secondary mechanism.
5. Assessment of the pharmacokinetic parameters of alendronate sodium
in modified-release matrix tablets administered on the oral route
Alendronate absorption occurs through passive diffusion, predominantly in the upper small
intestine (duodenum, jejunum, pH = 6-6.5), only a very small amount being also absorbed at
the gastric level [66].
Alendronate has a low oral bioavailability (0.6 to 0.9%) for doses ranging from 5 to 70 mg, in
conventional release formulations administered in the morning on an empty stomach or two
hours after breakfast. The bioavailability of the 10 mg tablet is 0.59, while the weekly dose
administration of 70 mg in tablets or solution leads to a bioavailability of 0.64% [67, 68]. These
values are determined by the following general characteristics of bisphosphonates:
• low lipophilicity, which restricts intra-and intercellular transport;
• high polarity given by the negative charge, which prevents paracellular transport [69].
Plasma distribution of alendronate exhibits very low concentrations (<5 ng/ml) at therapeutic
doses. Plasmatic t½ of alendronate is short 0.5 to 2 h compared to t½ in deposits at the site of
bone resorption that have values expressed in years for alendronate being > 10 years. Alendr‐
onate binds to plasma proteins in the ratio of 78% and also forms complexes with some divalent
cations, eg calcium, magnesium, iron [70].
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Excretion of alendronate is in the ratio of 99% in the feces and only 0.4% of the amount absorbed
is eliminated through the kidneys by glomerular filtration and tubular excretion.
Storage of alendronate in the bone tissue depends on the affinity for hydroxyapatite, the in
vitro affinity constant KL alendronat 2.9 x 106 mol/l [71].
Pharmacokinetically, alendronate does not present any significant differences between the
main groups of patients. The oral bioavailability of this active substance is similar in both
children and adults [66, 72]. The main objective of these studies is to evaluate the pharmaco‐
kinetic parameters of alendronate administered as modified-release matrix tablets.
5.1. Materials and methods
5.1.1. Materials
According to the results obtained in the research presented in subsections I-III, in order to
achieve the pharmacokinetic studies we selected matrix tablets formulas that exhibited optimal
characteristics of release (Table 8).
Ingredients (mg %)
Formulation
F2 F5 F8 Fm
C 971 15 15 15 -
CHTh - 6 - -
TMC - - 6 -
AL 13.05 13.05 13.05 13.05
Mg Stearate 0.5 0.5 0.5 0.5
Aerosil 0.5 0.5 0.5 0.5
Ludipress LCE 70.95 64.95 64.95 85.95
Table 8. The formulations of modified-release matrix tablets containing alendronate sodium
The tablets used in pharmacological research were prepared by direct compression, in
accordance with the technology described in Section I.
5.1.2. Methods
5.1.2.1. Experimental protocol
The research was performed on adult male dogs weighing 30-40 kg, divided into four groups
of 2 animals. Samples containing 20 mg alendronate sodium/tablet corresponding to the three
formulations studied were denoted F2, F5, F8. Fm, the control sample, comprised immediate-
release tablets with Alendronate sodium. The samples were administered to the four groups
as follows:
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• F2 →  group I;
• F5 →  group II;
• F8 →  group III
• Fm →  group IV.
The experimental study was conducted over a period of 48 hours and the tablets were
administered orally after the animals had fasted for 12 hours. During the experiment, the
animals had free access to water and food, except for 4 hours of food deprivation following
the administration of tablets.
Mention should be made that in the literature we did not identify the lethal dose 50 (DL 50) of
alendronate sodium administered to dogs, being conducted research by administering 200
mg / kg, a dose for which a mild renal toxicity was recorded [8, 73].
Preparation of the animals: 7 days prior to the experiment, each animal had free access to food
and water and was kept under normal conditions of light and temperature.
Blood sampling was performed using the following procedure:
• in order to collect the blood samples a catheter was placed in the femoral vein;
• to characterize the pharmacokinetic parameters, samples of 4 ml of blood were collected at
each moment in heparin vacutainers;
• sampling times were as follows: M 0 - prior to administration; M 1 - 30 min. after adminis‐
tration; M 2 - 1 h after administration; M 3 - 1 h and 30 min. after administration; M 4 - 2
hours after administration; M 5 - 2 h and 30 min. after administration; M 6 - 3 hours after
administration; M 7 - 3 h and 30 min. after administration; M 8 - 4 hours after administration;
M 9 - 6 hours after administration; M 10 - 8 h after administration; M 11 - 10 h after admin‐
istration; M 12 - 12 h after administration; M 13 - 24 hours after administration;
Processing of the blood samples consisted in:
• centrifugation after 30 minutes from collecting, at a speed of 3000 rpm, for 10 min.;
• serum was transferred into Ependorff test tubes and stored in a freezer, at – 20 °C, until the
HPLC quantitative analysis, according to the method described in section I.
All animals used in this study were clinically healthy and haematological and biochemical
analyses had been performed prior to the experiment.
5.1.2.2. Calculation of pharmacokinetic parameters
The main pharmacokinetic parameters that were evaluated directly, without a pharmacoki‐
netic modeling, based on the experimental data, are: the coordinates of the peak (Cmax and Tmax),
the areas under the curve (AUC0-t, AUC0-∞, AUCt-∞), the total clearance (Cl) and the average residual
time (MRT). These parameters are independent of the representation model of drug kinetics
in the body, and are very useful in bioavailability studies. A series of other parameters depend
on the pharmacokinetic model, so that it should be taken into account in calculating them.
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In the case of extravascular administration, the following parameters dependent on the model
can be calculated: elimination rate constant (ke), biological half-life (t1/2), absorption rate constant
(ka) and volume of distribution (Vd).
The main pharmacokinetic parameters calculated were:
• coordinates of the peak (Cmax and Tmax) – individual Cmax values expressed in μg/ml and Tmax,
expressed in hours, were obtained from the examination of experimental data;
• areas under the curve (AUC0-t, AUC0-∞, AUCt-∞) - the area under the plasma concentration
curve, noted AUC, is a parameter that reflects the extent of absorption in the administered
dose and that is proportional to the amount of drug that reaches the blood after oral
administration. As a result, this parameter is essential for the determination of bioavaila‐
bility.
• the area under the experimental plasmatic concentration curve AUC0-t was calculated by using
the trapezoidal rule, which is the most common method. We calculated the area from time
zero (initial time) to the time when the last blood sample was collected to determine the
concentration of the drug substance. The area under the curve is equal to the sum of the
areas of the trapezoids realized between two concentrations corresponding to two succes‐
sive collections of blood samples. The area of each trapezoid was calculated according to
the equation:
1
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where, n = number of trapezoids in which we divide the area under the curve (n is the number
of collections of biological samples);
• the total area under the plasmatic concentration curve AUC 0-∞ is equal to the sum of the area
under the experimental concentration curve and the area extrapolated from the time of the
last sample collection to infinity.
AUC0-∞ was calculated using the equation:
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where ke is calculated based on the end points of the plasma concentration curve in time.
Hydrophilic Matrix Tablets Based on Carbopol for Improving the Oral Bioavailability of Sodium Alendronate — …
http://dx.doi.org/10.5772/59510
153
• the extrapolated area is the area from the last sampling time extrapolated to infinity and it
was calculated by the equation:
n
t
e
cAUC k
¥ = (13)
where cn is plasma concentration of the last determination.
Totalclearance (Cl) – for oral administration, the absorbed dose and the total clearance cannot
be calculated exactly, so we determined the ratio:
Cl dose
F AUC= (14)
where F – correction factor
• the elimination rate constant (ke) was determined by the method of residuals, based on
plasmatic concentrations of the drug substance determined at different time intervals. This
method is also called the “least squares method” or the “method of the least sums of the
squares errors” and is used to estimate the true values with the help of the experimentally
determined values.
• biological half-life (t1/2) was calculated by the mathematical method. Starting from the equation
of the plasma concentration dependent on time in the disposal phase
0( ) ek tc t C e-= (15)
and knowing that the initial concentration is Co, and at the time t1/2 concentration is reduced
by half, the equation becomes
1/200 2
ek tCC e-= (16)
from which we obtain:
0
0
1/2
ln ln ln 2 0.6932
e e e
CC
t k k k
-
= = = (17)
where: ke was obtained by linear regression as a slope of the terminal phase of the logarith‐
mically transformed plasma concentration curve versus time
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• volume of distribution (Vd) – similar to total clearance, Vd cannot be evaluated exactly for
extravascular administration. Therefore the ratio is calculated:
0e
V dose
F k AUC¥= × (18)
Statistical analysis of data was performed using the PHARM-STAT program for the investi‐
gation of bioavailability.
5.2. Results and discussion
5.2.1. Bioavailability of alendronate sodium in modified-release hydrophilic matrix tablets based on
Carbopol
Results from the comparative analysis of serum concentrations of alendronate administered
as immediate-release tablets to the animals in (control) group IV and as modified-release
matrix tablets to group I, show a higher absorption of alendronate sodium from the modified-
release tablets.
We can distinguish two major phases in the evolution of the absorption of alendronate, in close
correlation with the swelling characteristics of matrix tablets. Modified-release matrix tablets
with sodium alendronate administered to the animals in group I generate an absorption
maximum at 2.5 to 3 hours, after which there is a plateau condition in the concentration range
of 0.25 to 0.30 μg/mL alendronate until time 12, i.e. 10 hours after administration (Figure 12).
Initially, in the first 1.5 hours after administration, the animals in control group IV exhibit an
alendronate serum concentration that is higher compared to group I. Subsequently, after about
2 hours from the administration, when the matrix tablet has hydrated and the phenomenon
of alendronate diffusion in the inner matrix layers occurs, the serum concentration of alendr‐
onate in the animals in group I increases significantly (Figure 13)
By analyzing the data obtained, we consider that the formulation of alendronate in matrix
tablets based on Carbopol C 971 resulted in a considerable increase in oral bioavailability.
5.2.2. Bioavailability of alendronate sodium in modified-release hydrophilic matrix tablets in the
presence of absorption promoters
In the first hour after administration, the animals in the control group had a higher serum
concentration of alendronate compared to the modified-release formulations (Figure 14).
Subsequently, at collection time 4, that is 1.5 hours after administration, the formulation
corresponding to the modified-release matrix tablets containing trimethil chitosan as an
absorption promoter exhibits the highest concentration. This superiority lasts until time 5, that
is 3 hours after administration (Figure 15). According to these results, we consider that over
this time the absorption enhancer action of trimethilchitosan manifests itself.
Hydrophilic Matrix Tablets Based on Carbopol for Improving the Oral Bioavailability of Sodium Alendronate — …
http://dx.doi.org/10.5772/59510
155
Figure 12. In vivo release of AL-Na from hydrophilic matrix tablets with modified release (0-12 hours)
Figure 13. In vivo release of AL-Na from hydrophilic matrix tablets with modified release (0-4 hours)
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Figure 14. In vivo release of AL-Na from hydrophilic matrix tablets with modified release in the presence of absorption
promotors (0-4 hours)
Figure 15. In vivo release of alendronate sodium from hydrophilic matrix tablets with modified release (0-12 hours)
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An unexpected development was recorded for animals in group II, which were administered
modified-release matrix tablets in which we had introduced chitosan as an absorption
promoter. The serum concentration of alendronate in this group was lower than in the control
formula throughout the experiment. There are two surprising aspects related to this: on the
one hand, the fact that chitosan does not act as absorption promoter and, on the other, that
there occurs a cancellation of the retardation effect and of the release optimization resulting
from the administration of the modified-release of matrix tablets based on Carbopol.
5.2.3. Pharmacokinetic parameters: Cmax, Tmax, t1/2, areas under the curve
The comprehensive review of the individual values of plasma concentrations over time and
of the corresponding individual graphs allows for a primary pharmacokinetic analysis of
results. Based on plasma concentration values over time the pharmacokinetic parameters
(Tmax, Cmax, AUC0-t, AUC0-∞, AUCt-∞, Cl, ke, t½, Vd) were determined. Subsequently, the data were
analyzed statistically to determine the possible existence of significant differences.
Mean Cmax peak plasma concentrations (Table 9) of the modified-release matrix tablets and of
the formula related to the control group, respectively, in a single dose study, reveal differences
between the formulations studied. Thus, for formula F2 given to group I, Cmax = 0,34μg/ml,
formula F5 associated with group II provides a Cmax = 0.24 μg/ml, formula F8, group III, has
Cmax = 0.48 μg/ml, and the control formula given to group IV, Cmax = 0.28 μg/ml. Result
processing through the ANOVA test shows that the differences between peak plasma con‐
centrations after administration of formulation F2, compared to control formulation and after
administration of F8 compared to the control, are not statistically significant. For parameter
Cmax only the differences between group I and III are statistically significant.
Mean value GROUPI II III IV
Cmax 0.34 0.24 0.48 0.28
Tmax 2.00 2.25 3.00 1.50
AUC 0-t 2.93 1.28 2.65 1.94
AUC 0-∞ 3.17 1.40 2.72 1.94
AUC t-∞ 0.24 0.12 0.07 0.00
% AUCextra 7.57 8.56 2.37 0.00
Cl 0.03 0.05 0.04 0.05
ke 0.08 0.08 0.13 0.08
t1/2 8.31 8.26 5.79 8.63
Vd 0.37 0.62 0.32 0.63
Table 9. Pharmacokinetic parameters of AL-Na
The mean values of time taken to reach peak concentration, Tmax (Table 9) exhibits equal values
for groups I and II compared to control group IV. The highest value was determined for group
Advances in Osteoporosis158
III, i.e. Tmax = 3 h. By applying a non-parametric test it was found that the differences are not
statistically significant.
The mean of the values of the extrapolated area AUC t-∞ is below 20% in all situations, which
proves the right choice for the last sample collection time. Analysis of the mean total area under
the plasma concentration-time (AUC0-∞) reveals differences between products. The highest
value was recorded for group I. Analysis of the mean values of Cl and Vd does not reveal
statistically significant differences between products.
5.3. Conclusions
The results obtained reveal an optimization of the bioavailability of alendronate administered
in modified-release matrix tablets from collection moment 5, i.e. two hours after administra‐
tion, as the animals in group I, corresponding to this formula, had a serum concentration of
alendronate superior to the control group.
The two absorption promoters used, trimethyl chitosan and chitosan, had completely different
influences on the absorption of alendronate in the modified-release matrix tablets. Thus,
trimethyl chitosan acted as an absorption promoter in the range 1.5 to 3 hours after adminis‐
tration, and caused the highest serum concentrations of alendronate, sometimes double
compared to the control. After that moment, concentrations are above the values of the control
group, but slightly lower than the values of group I, coresponding to the modified-release
matrix tablets based on Carbopol.
The administration of modified release tablets with alendronate sodium in which we associ‐
ated chitosan as absorption promoter has led to surprising results, because over the whole
experiment, the serum concentration of alendronate sodium was lower than of group IV
(control group). Chitosan exhibited virtually no absorption promoting action; it additionally
canceled the release retardation and optimization effect proved on group I after the adminis‐
tration of alendronate in modified-release matrix tablets based on carbopol.
6. Conclusions
The crosslinking degree of Carbopol has a major influence on the release properties of the
hydrophilic matrix tablets. The C71 and C971 Carbopol types, having a low crosslinking
degree, hydrate much better in pH 1.2, and this facilitates the AL-Na dissolution, its diffusion
through the gel layers of the matrix and, consequently, an optimized release of AL-Na. On the
contrary, C 971 – a polymer with a high crosslinking degree, slows the hydration process of
the matrix. Sort Carbopol 71 in a concentration of 15% results in hydrophilic matrix tablets
with optimal release of AL-Na. The different dissolution profile of Al-Na in the Carbopol-
based modified release matrix tablets is also confirmed by the values of the two control
parameters f1 and f2. Fitting the release data to the kinetic analysis with the Higuchi and the
Korsmeyer-Peppas model confirms the release of the Al-Na in the Carbopol-based matrix
tablets by a diffusion process. The Hopfenberg model applied to modified-release matrix
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tablets with a complex formulation based on associations of matrix-forming polymers to
highlight the involvement of erosion in the release of the active substance generated a good
fitting of the data (R2> 0.90), but the high values of the Akaike index do not allow the validation
of the model. In vivo studies have shown a higher bioavailability of AL-Na in modified release
matrix tablets at 1.5 hours after dosing. The results of the evaluation of the in vivo AL-Na release
indicate the optimization of the bioavailability of AL-Na in the Carbopol 71-based matrix
tablets, the optimal concentration being reached after 2 hours from the administration of the
tablet. The two absorption promoters used - chitosan and trimethyl chitosan - had a totally
different effect on alendronate absorption. Trimethyl chitosan showed a strong absorption
promoting effect by doubling AL-Na serum concentration while CHT did not show this effect.
According to the results obtained, Carbopol 71 is a good forming agent for modified-release
tablets to improve the oral bioavailability of AL-Na.
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